Skip to main content
SpringerLink
Log in

Management of Tardive Dyskinesia: Current Update

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Tardive dyskinesia is now widely recognised as a neurological side effect produced in susceptible individuals by ingestion of neuroleptics. In general, the disorder tends to be late in onset, but has also been reported in a small number of individuals who have received neuroleptics for only brief periods. Much effort has been spent searching for predisposing factors, but the only consistent findings are that subjects are usually elderly (and elderly females in particular), in addition to having been exposed to neuroleptic agents. More recently, the increased finding of the presence of buccolingual facial movements in elderly populations never exposed to neuroleptics may bring out a re-evaluation of the role of these agents in the aetiology of tardive dyskinesia.

Although much information on tardive dyskinesia has accrued in recent years, the precise definition, subtypes and pathophysiology remain unclear. With the development and availability of standardised rating scales, the clinical description of tardive dyskinesia has expanded from the initial buccolingual masticatory syndrome to include various abnormal movements of the fingers, arms, legs etc. Efforts have been made to distinguish withdrawal tardive dyskinesia from persistent tardive dyskinesia, but, irrespective of the classification, the disorder is in many instances reversible. However, it is impossible at present to predict the reversibility of each patient; therefore early detection of tardive dyskinesia remains an important clinical goal.

Pharmacological treatments are based on the currently accepted hypothesis of dopamine receptor hypersensitivity. Selective dopamine blockers (D2) which suppress tardive dyskinesia without causing an increase in Parkinsonian symptoms are at various stages of development. Acetylcholine and γ-aminobutyric acid (GABA) also appear to play a reciprocal role with dopamine as seen by moderate success using cholinergics and ‘GABAergics’. However, there is no completely satisfactory treatment at present, indicating that prevention must be the primary aim. Above all, clinicians should carefully evaluate the indication for neuroleptic drugs, and avoid their use in conditions which may be treated with more benign drugs.

A strategy for management of tardive dyskinesia is presented, and indications for withdrawing or continuing neuroleptics, the treatment of withdrawal dyskinesias and the role of experimental therapies are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • American Psychiatric Association: Task Force Report No. 18. Tardive Dyskinesia (Washington, D.C. 1979).

    Google Scholar 

  • Asnis, G.M.; Leopold, M.A.; Duvoisin, R.C. and Schwartz, A.H.: A survey of tardive dyskinesia in psychiatric outpatients. American Journal of Psychiatry 134: 1367–1370 (1977).

    PubMed  CAS  Google Scholar 

  • Baldessarini, R.J. and Tarsy, D.: Tardive Dyskinesia; Lipton et al. (Eds) Psychopharmacology: A Generation of Progress, pp.993–1004 (Raven Press, New York 1978).

    Google Scholar 

  • Bannet, J.; Belmaker, R.H. and Ebstein, R.P.: The effect of drug holidays in an animal model of tardive dyskinesia. Psychopharmacology 69: 223–224 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Berger, P.A. and Rexroth, K.: Tardive dyskinesia: Clinical, biological and pharmacological perspectives. Schizophrenic Bulletin 6(1): 102–116 (1980).

    CAS  Google Scholar 

  • Birket-Smith, E. and Anderson, J.V.: Treatment of side-effects of levodopa. Lancet 1: 431 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Bjorndal, N.; Casey, D.E.; Gerlach, J. et al.: The effect of levodopa in tardive dyskinesia; in Usdin et al. (Eds) Phenothiazines and structurally related drugs: Basic and Clinical Studies, pp.321–324 (Elsevier-North Holland, Amsterdam 1980).

    Google Scholar 

  • Carlsson, A. and Lindquist, M.: Effects of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica 20: 140–144 (1963).

    Article  PubMed  CAS  Google Scholar 

  • Casey, D.E. and Denney, D.: Pharmacological characterization of tardive dyskinesia. Psychopharmacology 54: 108 (1977).

    Article  Google Scholar 

  • Casey, D.E. and Hammerstad, J.P.: Sodium valproate in tardive dyskinesia. Journal of Clinical Psychiatry 40(11): 483–485 (1979).

    PubMed  CAS  Google Scholar 

  • Casey, D.E. and Gerlach J.: Oxiperomide in tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry 43: 264–267 (1980).

    Article  CAS  Google Scholar 

  • Casey, D.E.; Gerlach, J. and Simmelsgaard, H.: Sulpiride in tardive dyskinesia. Psychopharmacology 66: 73–77 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Casey, D.E.; Gerlach, J.; Magelund, G. and Christensen, T.R.: r-Acetylenic GABA in tardive dyskinesia. Archives of General Psychiatry 37: 1376–1379 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Chadwick, D.; Reynolds, E.H. and Marsden, C.S.: Anticonvulsant-induced dyskinesias: A comparison with dyskinesias induced by neuroleptic. Journal of Neurology, Neurosurgery and Psychiatry 39: 1210–1218 (1976).

    Article  CAS  Google Scholar 

  • Chouinard, G.: Early onset of tardive dyskinesia. American Journal of Psychiatry 136: 1323–1324 (1979).

    PubMed  CAS  Google Scholar 

  • Chouinard, G.; deMoutigny, C. and Annable, L: Tardive dyskinesia and antiparkinson medication. American Journal of Psychiatry 136: 228–229 (1979).

    PubMed  CAS  Google Scholar 

  • Chouinard, G.; Jones, P.; Annable, L. and Ross-Chouinard, A.: Sex differences and tardive dyskinesia. American Journal of Psychiatry 137: 507 (1980).

    PubMed  CAS  Google Scholar 

  • Crane, G.: Tardive dyskinesia in patients treated with major neuroleptics: A review of the literature. American Journal of Psychiatry 124 (Feb. suppl.): 140–148 (1968).

    Google Scholar 

  • Crane, G.E.: Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology 27: 426–430 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Crane, G.E.: Persistent dyskinesia. British Journal of Psychiatry 122: 395–405 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Crane, G.E. and Smeets, R.A.: Tardive dyskinesia and drug therapy in geriatric patients. Archives of General Psychiatry 30: 341–343 (1976).

    Article  Google Scholar 

  • Davis, K.L.; Hollister, LE. and Berger, P.A.; Baclofen in schizophrenia. Lancet 1: 1245 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Davis, K.L. and Berger, P.: Pharmacological investigations of the cholinergic imbalance hypothesis of movement disorders and psychosis. Biological Psychiatry 13: 23–49 (1978).

    PubMed  CAS  Google Scholar 

  • Davis, K.L.; Berger, P.A. and Hollister, L.E.: Clinical and preclinical experience with choline chloride in Huntington’s disease and tardive dyskinesia: Unanswered questions; in Barbeau et al. (Eds) Nutrition and the Brain, pp.305–315 (Raven Press, New York 1979).

    Google Scholar 

  • Davis, W.A.: Dyskinesia associated with chronic antihistamine use. New England Journal of Medicine 294: 113 (1976).

    Google Scholar 

  • Defraites, E.G., Jr; Davis, K.L. and Berger, P.A.: Coexisting tardive dyskinesia and parkinsonism: A case report. Biological Psychiatry 12: 267–272 (1977).

    Google Scholar 

  • Delay, J. and Deniker, O.: Le traitement des psychoses par line methode neurolytique derivee de l’hibernotherapie; in Congres des Medians Alienistes et Neurologistes de France, pp.497–502 (Luxembourg 1952).

  • Delwaide, P.J. and Desseilles, M.: Spontaneous buccolinguo-facial dyskinesia in the elderly. Acta Neurologica Scandinavica 56: 256–262 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Duvoisin, R.: Reserpine for tardive dyskinesia (contd). New England Journal of Medicine 286: 611 (1972).

    PubMed  CAS  Google Scholar 

  • Ey, H.; Faure, H. and Rappard, P.: Les reactions d’intolerance visa-vis de la chlorpromazine. Encephale 45: 790–796 (1956).

    PubMed  CAS  Google Scholar 

  • Fann, W.E. and Lake, C.R.: On the coexistence of parkinsonism and tardive dyskinesia. Diseases of the Nervous System 35: 325–326 (1974).

    Google Scholar 

  • Faurbye, A.; Rasch, P.J.; Peterson, P.B.; Brandborg, G. and Pakkenberg, H.: Neurological Symptoms in pharmacotherapy of psychoses. Acta Psychiatrica Scandinavica 40: 10–27 (1964).

    Article  PubMed  CAS  Google Scholar 

  • Freeman, H.: Pimozide as a neuroleptic. British Journal of Psychiatry 135: 82–83 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Gardos, G.; Cole, J.O. and Tarsy, D.: Withdrawal syndromes associated with antipsychotic drugs. American Journal of Psychiatry, 135: 1321–1324 (1978).

    PubMed  CAS  Google Scholar 

  • Gerlach, J.: The relationship between Parkinsonism and tardive dyskinesia. American Journal of Psychiatry 134: 781–784 (1977).

    PubMed  CAS  Google Scholar 

  • Gerlach, J.: Tardive dyskinesia. Danish Medical Bulletin 36: 209–245 (1979).

    Google Scholar 

  • Gerlach, J.; Reisby, N. and Randrup, A.: Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychoparmacologica 34: 21–35 (1974).

    Article  CAS  Google Scholar 

  • Godwin-Austin, R. and Clark, T.: Persistent phenothiazine dyskinesia treated with tetrabenazine. British Medical Journal 4: 25–26 (1971).

    Article  Google Scholar 

  • Gordon, J.; Borison, R. and Diamond, B.: Modulation of dopamine receptor sensitivity by estrogen. Biological Psychiatry 15: 389–396 (1980).

    PubMed  CAS  Google Scholar 

  • Growdon, J.; Hirsch, M.; Wurtman, R. and Wiener, W.: Oral choline administration to patients with tardive dyskinesia. New England Journal of Medicine 297: 524–527 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Growdon, J.: Lecithin can suppress tardive dyskinesia. New England Journal of Medicine 298: 1029 (1978).

    PubMed  CAS  Google Scholar 

  • Growdon, J.: Choline and lecithin administration to patients with tardive dyskinesia. Canadian Journal of Neurological Science 6: 80 (1979).

    Google Scholar 

  • Hall, R.A.; Jackson, R.A. and Swain, J.M.: Neurotoxic reactions resulting from chlorpromazine administration. Journal of the American Medical Association 141: 214–218 (1956).

    Article  Google Scholar 

  • Hunter, R.; Earl, C.J. and Thornicraft, S.: An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proceedings of the Royal Society of Medicine 517: 24–28 (1964).

    Google Scholar 

  • Jacobson, G.; Baldessarini, R.J. and Manschreck, T.: Tardive and withdrawal dyskinesia associated with haloperidol. American Journal of Psychiatry, 131: 910–913 (1974).

    PubMed  CAS  Google Scholar 

  • Jeste, D.V.; Potkin, S.G.; Sinha, S.; Feder, S. and Wyatt, R.J.: Tardive dyskinesia — reversible and persistent. Archives of General Psychiatry 36: 585–590 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Johnstone, E.C. and Owens, D.C.G.: The role of neuroleptic drugs in the production of movement disorders in schizophrenic patients. Presented at the 12th CINP Congress, Goteborg, Sweden (June 1980).

  • Jus, K.; Jus, A.; Gautier, J.-L; Villeneu, A.; Pires, P.; Pineau, R. and Villeneu, R.: Studies of the actions of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome. International Journal of Clinical Pharmacology 9: 138–145 (1974).

    CAS  Google Scholar 

  • Jus, A.; Jus, K. and Fontaine, P.: Long-term treatment of tardive dyskinesia. Journal of Clinical Psychiatry 40: 72–77 (1979).

    PubMed  CAS  Google Scholar 

  • Kazamatsuri, H.; Chien, C. and Cole, J.: Treatment of tardive dyskinesia: Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Archives of General Psychiatry 27: 95–99 (1972a).

    Article  PubMed  CAS  Google Scholar 

  • Kazamatsuri, H.; Chien, C. and Cole, J.: Treatment of tardive dyskinesia. Archives of General Psychiatry 27: 824–827 (1972b).

    Article  PubMed  CAS  Google Scholar 

  • Kazamatsuri, H.; Chien, C. and Cole, J.: Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry 130: 479–483 (1973).

    PubMed  CAS  Google Scholar 

  • Kebabian, J.W. and Calne, D.B.: Multiple receptors for dopamine. Nature 277: 93–96 (1978).

    Article  Google Scholar 

  • Kiloh, L.G.; Smith, S.J. and Williams, S.E.: Antiparkinson drugs as causal agents in tardive dyskinesia. Medical Journal of Australia 2: 591–593 (1973).

    PubMed  CAS  Google Scholar 

  • Klawans, H.L.: The Pharmacology of Extrapyramidal Movement Disorders (S. Karger, Basel 1973a).

    Google Scholar 

  • Klawans, H.L.: The pharmacology of tardive dyskinesia. American Journal of Psychiatry 130: 82–86 (1973b).

    PubMed  Google Scholar 

  • Klawans, H.L. and Rumovitz, R.: Effect of cholinergic and anti-cholinergic agents on tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry 27: 941–947 (1974).

    Article  Google Scholar 

  • Lal, S.: Comparison of thiopropazate and trifluoperazine on oral dyskinesia: A double-blind study. Current Therapeutic Research 16: 990–997 (1974).

    PubMed  CAS  Google Scholar 

  • Laska, E.; Varga, E.; Wanderlong, J.; Simpson, G.; Logemann, G.W. and Shah, B.K.: Patterns of psychotropic drug use for schizophrenia. Diseases of the Nervous System 34: 294–305 (1973).

    PubMed  CAS  Google Scholar 

  • Matthysse, S.: Antipsychotic drug actions: A clue to the neuropathology of schizophrenia. Federation Proceedings 32: 200–205 (1973).

    PubMed  CAS  Google Scholar 

  • Mattson, R.H. and Calverley, J.R.: Dextroamphetamine-sulfate-induced dyskinesias. Journal of American Medical Association 204: 400–402 (1968).

    Article  CAS  Google Scholar 

  • National Institute of Mental Health, Psychopharmacology Research Branch: Development of a Dyskinetic Movement Scale. ECDEU Intercom 4: 3–6 (1975).

    Google Scholar 

  • O’Flanagan, P.M.: Clonazepam in the treatment of drug-induced dyskinesia. British Medical Journal 1: 269–270 (1975).

    Article  PubMed  Google Scholar 

  • Ogita, K.; Yogi, G. and Itoh, H.: Comparative analysis of persistent dyskinesia of long-term usage with neuroleptics in France and in Japan. Folia Psychiatrica et Neurologica Japonica 29: 315–320 (1975).

    PubMed  CAS  Google Scholar 

  • Perris, C.; Dimitrijevic, P.; Jacobsson, L.; Paulsson, P.; Rapp, W. and Fröberg, H.: Tardive dyskinesia in psychiatric patients treated with neuroleptics. British Journal of Psychiatry 135: 509–514 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Pert, A.; Rosenblatt, J.; Sevel, C; Pert, C.B. and Bunney, W.E. Jr: Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 201: 171–173 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Pi, E. and Simpson, G.M.: Tardive dyskinesia and abnormal tongue movements. British Journal of Psychiatry 139: 526–528 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Prange, A.R.; Wilson, I.C.; Morris, C.E. and Hall, CD.: Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia. Psychopharmacology Bulletin 9: 36–37 (1973).

    Google Scholar 

  • Pryce, I.G. and Edwards, H.: Persistent oral dyskinesia in female mental hospital patients. British Journal of Psychiatry 112: 983–987 (1966).

    Article  PubMed  CAS  Google Scholar 

  • Quitkin, F.; Rifkin, A.; Gochfeld, L and Lkein, D.F.: Tardive dyskinesia. Are first signs reversible? American Journal of Psychiatry 134: 84–87 (1977).

    PubMed  CAS  Google Scholar 

  • Schonecker, M.: Ein eigentumlichen syndrom im oralen bereich bei Megaphen applikation. Nervenarzt 28: 35 (1957).

    Google Scholar 

  • Senn, H.; Jungi, W.; Kunz, H. and Poldinger, W.: Clozapine and agranulocytosis. Lancet 1: 547 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Sigwald, J.; Bouttier, D.; Raymond, C. and Piot, C: Quatre cas de dyskinesie famio-bucio-linguo-masticatrice à evolution prolongée secondaire à un traitment par les neuroleptiques. Revue Neurologique 100: 751–755 (1959).

    PubMed  CAS  Google Scholar 

  • Simpson, G.M. and Kline, N.S.: Tardive dyskinesia: Manifestation, incidence, etiology and treatment; in Yahr (Ed.) The Basai Ganglion, pp.427–432 (Raven Press, New York 1976a).

    Google Scholar 

  • Simpson, G.M. and Laska, E.: Sensitivity to a phenothiazine (butaperazine). Canadian Psychiatric Association Journal 13: 499–506 (1968).

    PubMed  CAS  Google Scholar 

  • Simpson, G.M.; Branchey, M.H. and Shrivastava, R.K.: Baclofen in schizophrenia. Lancet 1: 966–967 (1976b).

    Article  PubMed  CAS  Google Scholar 

  • Simpson, G.M.; Branchay, M.; Lee, J.; Voitashevsky, A. and Zoubok, B.: Lithium in tardive dyskinesia. Pharmakopsychiatrica 9: 76–89 (1976c).

    Article  CAS  Google Scholar 

  • Simpson, G.M.; Voitashevsky, A.; Young, M. and Lee, J.: Deanol in the treatment of tardive dyskinesia. Psychopharmacology 52: 256–261 (1977).

    Article  Google Scholar 

  • Simpson, G.M.; Varga, E.; Lee, J.H. and Zoubok, B.: Tardive dyskinesia and psychotropic drug history. Psychopharmacology 58: 117–124 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Simpson, G.M.; Lee, J.H.; Zoubok, B. and Gardos, G.: A rating scale for tardive dyskinesia. Psychopharmacology 58: 117–124 (1979).

    Article  Google Scholar 

  • Simpson, G.M.; Pi, E. and Sramek, J.: The current status of tardive dyskinesia. Journal of Psychiatrie Treatment and Evaluation. In press (1981).

    Google Scholar 

  • Singh, M.M.: Diazepam in the treatment of tardive dyskinesia: Preliminary observations. International Pharmacopsychiatry 11: 232–234 (1976).

    PubMed  CAS  Google Scholar 

  • Smith, R.C.; Tamminga, C.A.; Haraszti, J.; Pandey, G. and Davis, J.: Effects of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry 134: 763–768 (1977).

    PubMed  CAS  Google Scholar 

  • Smith, R.C.; Strizich, M. and Klass, D.: Drug history and tardive dyskinesia. American Journal of Psychiatry 135: 1402–1403 (1978).

    PubMed  CAS  Google Scholar 

  • Snyder, S.H.: Dopamine receptors, neuroleptics, and schizophrenia. American Journal of Psychiatry 138: 460–464 (1981).

    PubMed  CAS  Google Scholar 

  • Tamminga, G; Smith, R.; Chang, S. and Davis, J.: Cholinergic influences in tardive dyskinesia. American Journal of Psychiatry 134: 769–774 (1977).

    PubMed  CAS  Google Scholar 

  • Tamminga, C.A.; Crayton, J.W. and Chase, T.N.: Improvement in tardive dyskinesia after muscimol therapy. Archives of General Psychiatry 36: 595–598 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Tarsy, D. and Baldessarini, R.J.: Pharmacologically induced behavioural supersensitivity to apomorphine. Nature 245: 262–263 (1973).

    CAS  Google Scholar 

  • Tarsy, D. and Baldessarini, R.J.: The Pathophysiologic Basis of Tardive Dyskinesia. Presented at the Symposium on Biochemical Basis of Drug Side Effects of Psychiatry, San Francisco, California (1976).

  • Tarsy, D. and Bralower, M.: Tardive dyskinesia in young adults. American Journal of Psychiatry 134: 1032–1034 (1977).

    PubMed  CAS  Google Scholar 

  • Turek, I.; Kurland, A.; Hanlon, T. and Bohm, M.: Tardive dyskinesia: In relation to neuroleptic and antiparkinson drugs. British Journal of Psychiatry 121: 605–612 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Uhrbrand, L and Faurbye, A.: Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia 1: 406–418 (1960).

    Article  Google Scholar 

  • Verga, E.; Sugerman, A.A.; Varga, V.; Zomorodi, A.; Zomorodi, W. and Menken, M.: Prevalence of spontaneous oral dyskinesia in elderly persons. Presented at 12th CINP Congress, Göteborg, Sweden, June (1980).

  • Viukari, M. and Linnoila, M.: Effect of fusaric acid on tardive dyskinesia and mental state in psychogeriatric patients. Acta Psychiatrica Scandinavica 56: 57–61 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Wolf, S.M.: Reserpine: Cause and treatment of oral facial dyskinesia. Bulletin of the Los Angeles Neurological Society 38: 80–84 (1973).

    CAS  Google Scholar 

  • Yagi, G.; Ogita, K.; Ohtsuka, N.; Itoh, H. and Miura, S.: Persistent dyskinesia after long-term treatment with neuroleptics in Japan. Keio Journal of Medicine 25: 27–35 (1976).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Southem California School of Medicine, 1934 Hospital Place, Los Angeles, California, 90033, USA

    George M. Simpson, Edmond H. Pi & John J. Sramek Jr

Authors
  1. George M. Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edmond H. Pi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John J. Sramek Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson, G.M., Pi, E.H. & Sramek, J.J. Management of Tardive Dyskinesia: Current Update. Drugs 23, 381–393 (1982). https://doi.org/10.2165/00003495-198223050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198223050-00003

Keywords

Search

Navigation